Find a clinical trial

FindClinicalTrial

If you have questions about clinical trials or want help finding the right one for you, contact our:

Patient Engagement Center Phone: 844-552-2734

This is a preliminary search of all open and enrolling clinical trials across our regions and affiliate organizations that have sponsors' permission to publish to this website.

Please use the filtering options in the right column to refine your search. Otherwise ALL open and enrolling clinical trials will display below.

« Previous 123 Next »
Viewing Page 1 of 3 | Showing Results 1 - 5 of 15

A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis

Inclusion Criteria: Are ambulatory. Diagnosis of nonradiographic axial spondyloarthritis (nr-axSpA) and fulfilling the 2009 ASAS classification...

Kalpita Hatti, M.D.
  • Kadlec Research

A Phase 3b/4 Randomized Double Blind Placebo Controlled Study Of Methotrexate (MTX) Withdrawal In Subjects With Rheumatoid Arthritis (RA) Treated With Tofacitinib 11mg Modified Release (MR) Formulation

This study is designed to evaluate the efficacy and safety of tofacitinib modified release formulation (11mg QD) versus tofacitinib modified...

Philip Mease, M.D.
  • Swedish Medical Center

Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis

Inclusion Criteria: Patient must be a male or female 18 years of age or older as the study is intended to assess Golimumab intravenous (IV) and...

Kalpita Hatti, M.D.
  • Kadlec Research

Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation

Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly...

Philip Mease, M.D.
  • Swedish Medical Center

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis After 16 Weeks of Treatment Compared to Placebo and to Assess the Safety, Tolerability and Efficacy up to 52 Weeks

To demonstrate that the efficacy of secukinumab 300 mg at Week 16 is superior to placebo in adult patients with active PsA based on the proportion...

Philip Mease, M.D.
  • Swedish Medical Center
« Previous 123 Next »
Viewing Page 1 of 3 | Showing Results 1 - 5 of 15